首页 > 最新文献

Journal of Rheumatic Diseases最新文献

英文 中文
Magnetic resonance images of myalgia with different etiologies in a patient with systemic lupus erythematosus 一名系统性红斑狼疮患者不同病因引起的肌痛的磁共振图像
IF 2 Q3 Medicine Pub Date : 2024-06-05 DOI: 10.4078/jrd.2024.0050
Hideki Nakamura, Masahiro Nishihara, S. Asatani, Yuko Kobashi
{"title":"Magnetic resonance images of myalgia with different etiologies in a patient with systemic lupus erythematosus","authors":"Hideki Nakamura, Masahiro Nishihara, S. Asatani, Yuko Kobashi","doi":"10.4078/jrd.2024.0050","DOIUrl":"https://doi.org/10.4078/jrd.2024.0050","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141382165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study 韩国巨细胞动脉炎患者的临床特征和病程:一项多中心回顾性研究
IF 2 Q3 Medicine Pub Date : 2024-05-14 DOI: 10.4078/jrd.2024.0007
Jee-In Lee, Jun Won Park, Youjin Jung, K. Shin, S. Choi, Eun Ha Kang, Yun Jong Lee, J. J. Yoo, Y. Ha
{"title":"Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study","authors":"Jee-In Lee, Jun Won Park, Youjin Jung, K. Shin, S. Choi, Eun Ha Kang, Yun Jong Lee, J. J. Yoo, Y. Ha","doi":"10.4078/jrd.2024.0007","DOIUrl":"https://doi.org/10.4078/jrd.2024.0007","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140980006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells. 重组人骨形态发生蛋白-2 和骨保护蛋白-Fc 在 MC3T3-E1 细胞中的作用。
IF 2 Q3 Medicine Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI: 10.4078/jrd.2023.0043
Sang-Hyon Kim, Hye-Jung Choi, Sang-Min Lee, Dae Sung Yoon, Chang-Nam Son

Objective: We compared the osteoblastogenesis by serially administrating recombinant human bone morphogenetic protein-2 (rhBMP-2) and osteoprotegerin-immunoglobulin Fc segment complex (OPG-Fc).

Methods: The MC3T3-E1 preosteoblast cell line was differentiated for 1, 3, and 7 days with a treatment of OPG-Fc in 10~200 ng/mL concentration and the cell viability was evaluated by Cell Counting Kit-8 analysis. The level of differentiation from MC3T3-E1 cells to osteoblasts was determined by alkaline phosphatase activity. The level of runt domain-containing transcription factor 2 (Runx2) and osteopontin (OPN) manifestation, involved in osteoblast differentiation, was examined by real-time polymerase chain reaction and western blotting.

Results: During MC3T3-E1 cell differentiation, the differentiation level was high with 1-day treatment using 100 ng/mL OPG-Fc. The treatment with 50 ng/mL rhBMP-2 for 7 days, followed by 1-day treatment with 100 ng/mL OPG-Fc produced the highest differentiation level, which was approximately 5.3 times that of the control group (p<0.05). The expression of Runx2 mRNA significantly increased, reaching 2.5 times the level of the control group under the condition of 7-day treatment with rhBMP-2 and 1-day treatment with OPG-Fc (p<0.001). The expression of Runx2 protein significantly increased to approximately 5.7 times that of the control group under the condition of 7-day treatment with rhBMP-2, followed by 1-day treatment with OPG-Fc (p<0.01). The expression of OPN protein showed no change from that of the control group under various conditions of rhBMP-2 and OPG-Fc combinations.

Conclusion: These results imply that the treating preosteoblasts with rhBMP-2 first and then with OPG-Fc increased osteoblast differentiation efficacy.

目的我们比较了连续给予重组人骨形态发生蛋白-2(rhBMP-2)和骨保护剂-免疫球蛋白 Fc 段复合物(OPG-Fc)的成骨作用:用 10~200 ng/mL 浓度的 OPG-Fc 对 MC3T3-E1 前成骨细胞系进行 1、3 和 7 天的分化,并用细胞计数试剂盒-8 分析评估细胞活力。通过碱性磷酸酶活性测定 MC3T3-E1 细胞向成骨细胞的分化水平。实时聚合酶链反应和免疫印迹法检测了参与成骨细胞分化的含runt结构域转录因子2(Runx2)和骨生成素(OPN)的表达水平:结果:在 MC3T3-E1 细胞分化过程中,使用 100 ng/mL OPG-Fc 处理 1 天,分化水平较高。用 50 ng/mL rhBMP-2 处理 7 天后,再用 100 ng/mL OPG-Fc 处理 1 天,分化水平最高,约为对照组的 5.3 倍(pConclusion):这些结果表明,先用 rhBMP-2 处理前成骨细胞,然后再用 OPG-Fc 处理,可提高成骨细胞的分化效率。
{"title":"Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells.","authors":"Sang-Hyon Kim, Hye-Jung Choi, Sang-Min Lee, Dae Sung Yoon, Chang-Nam Son","doi":"10.4078/jrd.2023.0043","DOIUrl":"10.4078/jrd.2023.0043","url":null,"abstract":"<p><strong>Objective: </strong>We compared the osteoblastogenesis by serially administrating recombinant human bone morphogenetic protein-2 (rhBMP-2) and osteoprotegerin-immunoglobulin Fc segment complex (OPG-Fc).</p><p><strong>Methods: </strong>The MC3T3-E1 preosteoblast cell line was differentiated for 1, 3, and 7 days with a treatment of OPG-Fc in 10~200 ng/mL concentration and the cell viability was evaluated by Cell Counting Kit-8 analysis. The level of differentiation from MC3T3-E1 cells to osteoblasts was determined by alkaline phosphatase activity. The level of runt domain-containing transcription factor 2 (Runx2) and osteopontin (OPN) manifestation, involved in osteoblast differentiation, was examined by real-time polymerase chain reaction and western blotting.</p><p><strong>Results: </strong>During MC3T3-E1 cell differentiation, the differentiation level was high with 1-day treatment using 100 ng/mL OPG-Fc. The treatment with 50 ng/mL rhBMP-2 for 7 days, followed by 1-day treatment with 100 ng/mL OPG-Fc produced the highest differentiation level, which was approximately 5.3 times that of the control group (p<0.05). The expression of Runx2 mRNA significantly increased, reaching 2.5 times the level of the control group under the condition of 7-day treatment with rhBMP-2 and 1-day treatment with OPG-Fc (p<0.001). The expression of Runx2 protein significantly increased to approximately 5.7 times that of the control group under the condition of 7-day treatment with rhBMP-2, followed by 1-day treatment with OPG-Fc (p<0.01). The expression of OPN protein showed no change from that of the control group under various conditions of rhBMP-2 and OPG-Fc combinations.</p><p><strong>Conclusion: </strong>These results imply that the treating preosteoblasts with rhBMP-2 first and then with OPG-Fc increased osteoblast differentiation efficacy.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report. 用芦昔替尼成功治疗一名系统性红斑狼疮患者的嗜血细胞淋巴组织细胞增多症:病例报告。
IF 2 Q3 Medicine Pub Date : 2024-04-01 Epub Date: 2023-06-12 DOI: 10.4078/jrd.2023.0027
Ji In Jung, Ju Yeon Kim, Mi Hyeon Kim, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hematological disorder characterized by uncontrolled activation of CD8+ T and natural killer cells, leading to a cytokine storm and severe organ dysfunction. Although secondary HLH related to autoimmune diseases usually demonstrates a good treatment response to immunosuppressive therapy for underlying conditions, there is no consensus regarding the treatment in case of unresponsiveness to the treatment. Herein, we present a case of HLH that was unresponsive to high-dose glucocorticoid and cyclosporine treatment in a patient with newly diagnosed systemic lupus erythematosus. The patient's clinical features and laboratory abnormalities rapidly improved with ruxolitinib, an oral Janus kinase 1 and 2 (JAK1/2) inhibitor. This result suggests that blocking JAK-STAT pathway may be a potential treatment option in patients with refractory HLH secondary to autoimmune diseases.

嗜血细胞淋巴组织细胞增多症(HLH)是一种罕见的、危及生命的血液病,其特点是 CD8+ T 细胞和自然杀伤细胞失控活化,导致细胞因子风暴和严重的器官功能障碍。虽然与自身免疫性疾病相关的继发性 HLH 通常对基础疾病的免疫抑制治疗表现出良好的治疗反应,但对于治疗无效时的治疗方法还没有达成共识。在此,我们介绍了一例对大剂量糖皮质激素和环孢素治疗无反应的 HLH 病例,患者为新诊断的系统性红斑狼疮。口服 Janus 激酶 1 和 2(JAK1/2)抑制剂芦可利替尼后,患者的临床特征和实验室异常迅速改善。这一结果表明,阻断JAK-STAT通路可能是继发于自身免疫性疾病的难治性HLH患者的一种潜在治疗选择。
{"title":"Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report.","authors":"Ji In Jung, Ju Yeon Kim, Mi Hyeon Kim, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park","doi":"10.4078/jrd.2023.0027","DOIUrl":"10.4078/jrd.2023.0027","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hematological disorder characterized by uncontrolled activation of CD8+ T and natural killer cells, leading to a cytokine storm and severe organ dysfunction. Although secondary HLH related to autoimmune diseases usually demonstrates a good treatment response to immunosuppressive therapy for underlying conditions, there is no consensus regarding the treatment in case of unresponsiveness to the treatment. Herein, we present a case of HLH that was unresponsive to high-dose glucocorticoid and cyclosporine treatment in a patient with newly diagnosed systemic lupus erythematosus. The patient's clinical features and laboratory abnormalities rapidly improved with ruxolitinib, an oral Janus kinase 1 and 2 (JAK1/2) inhibitor. This result suggests that blocking JAK-STAT pathway may be a potential treatment option in patients with refractory HLH secondary to autoimmune diseases.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87991618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning models with time-series clinical features to predict radiographic progression in patients with ankylosing spondylitis. 利用时间序列临床特征的机器学习模型预测强直性脊柱炎患者的放射学进展。
IF 2 Q3 Medicine Pub Date : 2024-04-01 Epub Date: 2023-12-20 DOI: 10.4078/jrd.2023.0056
Bon San Koo, Miso Jang, Ji Seon Oh, Keewon Shin, Seunghun Lee, Kyung Bin Joo, Namkug Kim, Tae-Hwan Kim

Objective: Ankylosing spondylitis (AS) is chronic inflammatory arthritis causing structural damage and radiographic progression to the spine due to repeated and continuous inflammation over a long period. This study establishes the application of machine learning models to predict radiographic progression in AS patients using time-series data from electronic medical records (EMRs).

Methods: EMR data, including baseline characteristics, laboratory findings, drug administration, and modified Stoke AS Spine Score (mSASSS), were collected from 1,123 AS patients between January 2001 and December 2018 at a single center at the time of first (T1), second (T2), and third (T3) visits. The radiographic progression of the (n+1)th visit (Pn+1=(mSASSSn+1-mSASSSn)/(Tn+1-Tn)≥1 unit per year) was predicted using follow-up visit datasets from T1 to Tn. We used three machine learning methods (logistic regression with the least absolute shrinkage and selection operation, random forest, and extreme gradient boosting algorithms) with three-fold cross-validation.

Results: The random forest model using the T1 EMR dataset best predicted the radiographic progression P2 among the machine learning models tested with a mean accuracy and area under the curves of 73.73% and 0.79, respectively. Among the T1 variables, the most important variables for predicting radiographic progression were in the order of total mSASSS, age, and alkaline phosphatase.

Conclusion: Prognosis predictive models using time-series data showed reasonable performance with clinical features of the first visit dataset when predicting radiographic progression.

目的:强直性脊柱炎(AS)是一种慢性炎症性关节炎,由于长期反复持续的炎症,会造成脊柱结构损伤和影像学进展。本研究利用电子病历(EMR)中的时间序列数据,建立了应用机器学习模型预测强直性脊柱炎患者放射学进展的方法:2001年1月至2018年12月期间,在一个中心收集了1123名强直性脊柱炎患者首次(T1)、第二次(T2)和第三次(T3)就诊时的EMR数据,包括基线特征、实验室检查结果、用药情况和改良斯托克强直性脊柱炎脊柱评分(mSASSS)。利用从T1到Tn的随访数据集预测了第(n+1)次随访的放射学进展(Pn+1=(mSASSSn+1-mSASSSn)/(Tn+1-Tn)≥每年1个单位)。我们使用了三种机器学习方法(带有最小绝对收缩和选择操作的逻辑回归、随机森林和极梯度提升算法),并进行了三次交叉验证:在测试的机器学习模型中,使用 T1 EMR 数据集的随机森林模型对放射学进展 P2 的预测效果最好,平均准确率和曲线下面积分别为 73.73% 和 0.79。在T1变量中,预测放射学进展最重要的变量依次为总mSASSS、年龄和碱性磷酸酶:使用时间序列数据的预后预测模型与首次就诊数据集的临床特征相比,在预测放射学进展方面表现出了合理的性能。
{"title":"Machine learning models with time-series clinical features to predict radiographic progression in patients with ankylosing spondylitis.","authors":"Bon San Koo, Miso Jang, Ji Seon Oh, Keewon Shin, Seunghun Lee, Kyung Bin Joo, Namkug Kim, Tae-Hwan Kim","doi":"10.4078/jrd.2023.0056","DOIUrl":"10.4078/jrd.2023.0056","url":null,"abstract":"<p><strong>Objective: </strong>Ankylosing spondylitis (AS) is chronic inflammatory arthritis causing structural damage and radiographic progression to the spine due to repeated and continuous inflammation over a long period. This study establishes the application of machine learning models to predict radiographic progression in AS patients using time-series data from electronic medical records (EMRs).</p><p><strong>Methods: </strong>EMR data, including baseline characteristics, laboratory findings, drug administration, and modified Stoke AS Spine Score (mSASSS), were collected from 1,123 AS patients between January 2001 and December 2018 at a single center at the time of first (T1), second (T2), and third (T3) visits. The radiographic progression of the (n+1)th visit (Pn+1=(mSASSSn+1-mSASSSn)/(Tn+1-Tn)≥1 unit per year) was predicted using follow-up visit datasets from T1 to Tn. We used three machine learning methods (logistic regression with the least absolute shrinkage and selection operation, random forest, and extreme gradient boosting algorithms) with three-fold cross-validation.</p><p><strong>Results: </strong>The random forest model using the T1 EMR dataset best predicted the radiographic progression P2 among the machine learning models tested with a mean accuracy and area under the curves of 73.73% and 0.79, respectively. Among the T1 variables, the most important variables for predicting radiographic progression were in the order of total mSASSS, age, and alkaline phosphatase.</p><p><strong>Conclusion: </strong>Prognosis predictive models using time-series data showed reasonable performance with clinical features of the first visit dataset when predicting radiographic progression.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study. 类风湿性关节炎患者服用单一常规缓解病情抗风湿药(cDMARD)加抗肿瘤坏死因子药与服用多种 cDMARDs 的实际效果:一项前瞻性观察研究。
IF 2 Q3 Medicine Pub Date : 2024-04-01 Epub Date: 2024-01-29 DOI: 10.4078/jrd.2023.0045
Min Wook So, Sang-Hyon Kim, Dong Wook Kim, Yoon-Kyoung Sung, Jung-Yoon Choe, Sang-Il Lee, Jin-Wuk Hur, Hye-Soon Lee, Sang-Heon Lee, Jin Ran Kim, PharmD

Objective: The objective of this prospective, observational multicenter study (NCT03264703) was to compare the effectiveness of single conventional disease-modifying anti-rheumatic drug (cDMARD) plus anti-tumor necrosis factor (TNF) therapy versus multiple cDMARD treatments in patients with moderate-to-severe rheumatoid arthritis (RA) following cDMARD failure in the real-world setting in South Korea.

Methods: At the treating physicians' discretion, patients received single cDMARD plus anti-TNF therapy or multiple cDMARDs. Changes from baseline in disease activity score 28-joint count with erythrocyte sedimentation rate (DAS28-ESR), corticosteroid use, and Korean Health Assessment Questionnaire (KHAQ-20) scores were evaluated at 3, 6, and 12 months.

Results: Of 207 enrollees, the final analysis included 45 of 73 cDMARD plus anti-TNF and 91 of 134 multiple-cDMARD recipients. There were no significant between-group differences (BGDs) in ANCOVA-adjusted changes from baseline in DAS28-ESR at 3, 6 (primary endpoint), and 12 months (BGDs -0.18, -0.38, and -0.03, respectively). More cDMARD plus anti-TNF than multiple-cDMARD recipients achieved a >50% reduction from baseline in corticosteroid dosage at 12 months (35.7% vs 14.6%; p=0.007). Changes from baseline in KHAQ-20 scores at 3, 6, and 12 months were significantly better with cDMARD plus anti-TNF therapy than with multiple cDMARDs (BGD -0.18, -0.19, and -0.19 points, respectively; all p0.024).

Conclusion: In the real-world setting, relative to multiple cDMARDs, single cDMARD plus anti-TNF therapy significantly improved quality-of-life scores and reduced corticosteroid use, with no significant BGD in disease activity, in RA patients in whom previous cDMARD therapy had failed.

研究目的这项前瞻性多中心观察性研究(NCT03264703)的目的是在韩国的实际环境中,比较单一常规改善病情抗风湿药(cDMARD)加抗肿瘤坏死因子(TNF)疗法与多种cDMARD疗法对cDMARD治疗失败的中重度类风湿关节炎(RA)患者的疗效:由主治医生决定,患者接受单一 cDMARD 加抗 TNF 治疗或多种 cDMARDs 治疗。在3、6和12个月时评估疾病活动评分28-关节计数和红细胞沉降率(DAS28-ESR)、皮质类固醇激素使用量和韩国健康评估问卷(KHAQ-20)评分与基线相比的变化:在207名患者中,最终分析包括73名cDMARD加抗TNF患者中的45名和134名多重cDMARD患者中的91名。经方差分析调整后,3、6(主要终点)和12个月时DAS28-ESR与基线相比的变化无明显组间差异(BGD)(BGD分别为-0.18、-0.38和-0.03)。12个月时,皮质类固醇用量比基线减少50%以上的cDMARD加抗TNF受试者多于多重cDMARD受试者(35.7%对14.6%;P=0.007)。3、6和12个月时KHAQ-20评分与基线相比的变化,cDMARD加抗TNF疗法明显优于多种cDMARDs疗法(BGD分别为-0.18、-0.19和-0.19分;所有P均≤0.024):结论:在真实世界环境中,相对于多种cDMARDs疗法,单一cDMARDs加抗TNF疗法能显著改善既往cDMARD疗法失败的RA患者的生活质量评分,减少皮质类固醇的使用,但疾病活动性没有明显的BGD。
{"title":"Real-world effectiveness of a single conventional disease-modifying anti-rheumatic drug (cDMARD) plus an anti-TNF agent versus multiple cDMARDs in rheumatoid arthritis: a prospective observational study.","authors":"Min Wook So, Sang-Hyon Kim, Dong Wook Kim, Yoon-Kyoung Sung, Jung-Yoon Choe, Sang-Il Lee, Jin-Wuk Hur, Hye-Soon Lee, Sang-Heon Lee, Jin Ran Kim, PharmD","doi":"10.4078/jrd.2023.0045","DOIUrl":"10.4078/jrd.2023.0045","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this prospective, observational multicenter study (NCT03264703) was to compare the effectiveness of single conventional disease-modifying anti-rheumatic drug (cDMARD) plus anti-tumor necrosis factor (TNF) therapy versus multiple cDMARD treatments in patients with moderate-to-severe rheumatoid arthritis (RA) following cDMARD failure in the real-world setting in South Korea.</p><p><strong>Methods: </strong>At the treating physicians' discretion, patients received single cDMARD plus anti-TNF therapy or multiple cDMARDs. Changes from baseline in disease activity score 28-joint count with erythrocyte sedimentation rate (DAS28-ESR), corticosteroid use, and Korean Health Assessment Questionnaire (KHAQ-20) scores were evaluated at 3, 6, and 12 months.</p><p><strong>Results: </strong>Of 207 enrollees, the final analysis included 45 of 73 cDMARD plus anti-TNF and 91 of 134 multiple-cDMARD recipients. There were no significant between-group differences (BGDs) in ANCOVA-adjusted changes from baseline in DAS28-ESR at 3, 6 (primary endpoint), and 12 months (BGDs -0.18, -0.38, and -0.03, respectively). More cDMARD plus anti-TNF than multiple-cDMARD recipients achieved a >50% reduction from baseline in corticosteroid dosage at 12 months (35.7% vs 14.6%; p=0.007). Changes from baseline in KHAQ-20 scores at 3, 6, and 12 months were significantly better with cDMARD plus anti-TNF therapy than with multiple cDMARDs (BGD -0.18, -0.19, and -0.19 points, respectively; all p<i>≤</i>0.024).</p><p><strong>Conclusion: </strong>In the real-world setting, relative to multiple cDMARDs, single cDMARD plus anti-TNF therapy significantly improved quality-of-life scores and reduced corticosteroid use, with no significant BGD in disease activity, in RA patients in whom previous cDMARD therapy had failed.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Juvenile systemic sclerosis. 青少年系统性硬化症。
IF 2 Q3 Medicine Pub Date : 2024-04-01 DOI: 10.4078/jrd.2024.0018
Young Dae Kim
{"title":"Juvenile systemic sclerosis.","authors":"Young Dae Kim","doi":"10.4078/jrd.2024.0018","DOIUrl":"10.4078/jrd.2024.0018","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical treatment of osteoarthritis: botanical pharmacologic aspect 骨关节炎的药物治疗:植物药理方面
IF 2 Q3 Medicine Pub Date : 2024-02-01 DOI: 10.4078/jrd.2023.0084
J. Park, Sung Won Lee
{"title":"Medical treatment of osteoarthritis: botanical pharmacologic aspect","authors":"J. Park, Sung Won Lee","doi":"10.4078/jrd.2023.0084","DOIUrl":"https://doi.org/10.4078/jrd.2023.0084","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139880743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical treatment of osteoarthritis: botanical pharmacologic aspect 骨关节炎的药物治疗:植物药理方面
IF 2 Q3 Medicine Pub Date : 2024-02-01 DOI: 10.4078/jrd.2023.0084
J. Park, Sung Won Lee
{"title":"Medical treatment of osteoarthritis: botanical pharmacologic aspect","authors":"J. Park, Sung Won Lee","doi":"10.4078/jrd.2023.0084","DOIUrl":"https://doi.org/10.4078/jrd.2023.0084","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139821081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Piriformis syndrome as an overlooked cause of pain in a patient with axial spondyloarthritis: a case report 被忽视的轴性脊柱关节炎患者疼痛原因之梨状肌综合征:病例报告
IF 2 Q3 Medicine Pub Date : 2024-01-18 DOI: 10.4078/jrd.2023.0066
E. A. Tezcan, K. Erol, I. Gezer
{"title":"Piriformis syndrome as an overlooked cause of pain in a patient with axial spondyloarthritis: a case report","authors":"E. A. Tezcan, K. Erol, I. Gezer","doi":"10.4078/jrd.2023.0066","DOIUrl":"https://doi.org/10.4078/jrd.2023.0066","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139613931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Rheumatic Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1